(GOG 3003) A Randomized, Double-Blind, Placebo-Controlled Phase II Study of VTX-2337 (IND #78,416) in Combination with Pegylated Liposomal Doxorubicin (PLD) in Patients with Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Description: 

To compare the overall survival (OS) of patients treated with VTX-2337 + PLD versus those treated with PLD alone in women with recurrent or persistent, epithelial ovarian, fallopian tube or primary peritoneal cancer.

Study Number: 

NCG 233413

Phase: 
II
Principal Investigator: 
ClinicalTrials.Gov ID: 
NCT01666444

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail askrpci@roswellpark.org.